EIPR believes that the Egyptian government should negotiate with the new drug manufacturer from a position of strength as this drug cannot be imported without receiving an Egyptian license and conducting the needed clinical trials.
Tags: Hepatitis C
The Egyptian Initiative for Personal Rights (EIPR) issued a briefing note on the World Hepatitis Day, 28 July 2011, presenting the most important features of the debate over the quality, safety and efficacy (QSE) of long-lasting interferon, produc
The Egyptian Initiative for Personal Rights (EIPR) welcomed today Minister of Health Decree 371/2010 prohibiting discrimination against people with hepatitis C and upholding their right to work.
